Lack of pharmacokinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin/ tazobactam in healthy participants

Journal of Clinical Pharmacology

Volumn 49, Issue 7, 2009, Pages 816-823

  Wong, Shekman L ^a   Sörgel, Fritz ^b,c   Kinzig, Martina ^b   Goldberg, Michael R ^a   Kitt, Michael M ^a   Barriere, Steven L ^a  

^a THERAVANCE INC   (United States)

^b IBMP (Institute of Biomedical and Pharmaceutical Research)   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Aztreonam; Pharmacokinetics; Piperacillin tazobactam; Telavancin

Indexed keywords

AZTREONAM; DRUG METABOLITE; PIPERACILLIN PLUS TAZOBACTAM; TELAVANCIN; THRX 651540; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; DRUG URINE LEVEL; DYSGEUSIA; FEMALE; HALF LIFE TIME; HUMAN; HYPERSENSITIVITY REACTION; MALE; MATHEMATICAL ANALYSIS; PARAMETER; PHASE 1 CLINICAL TRIAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; AZTREONAM; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; DYSGEUSIA; FEMALE; HUMANS; MALE; MIDDLE AGED; PENICILLANIC ACID; PIPERACILLIN;

EID: 67650478321     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009337133     Document Type: Article

References (11)

1. Rice LB Antimicrobial resistance in gram-positive bacteria. Am J Med. 2006 ; 119 (suppl 1). S11 - S19.
2. Jones RN Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis. 2006 ; 42 (suppl 1). S13 - S24.
3. Higgins DL, Chang R., Debabov DV, et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2005 ; 49: 1127-1134. (Pubitemid 40327734)
4. Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis. 2008 ; 46: 1683-1693. (Pubitemid 351706765)
5. Rubinstein E., Corey GR, Stryjewski ME, et al. Telavancin for hospital-acquired pneumonia, including ventilator-associated pneumonia: the ATTAIN studies. Clin Microbiol Infect. 2008 ; 14 (suppl 7). S14 - S15. Abstract O75.
6. Sun HK, Duchin K., Nightingale CH, Shaw JP, Seroogy J., Nicolau DP Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob Agents Chemother. 2006 ; 50: 788-790. (Pubitemid 43191003)
7. Shaw JP, Seroogy J., Kaniga K., Higgins DL, Kitt M., Barriere S. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother. 2005 ; 49: 195-201. (Pubitemid 40065793)
8. Scully BE, Swabb EA, Neu HC Pharmacology of aztreonam after intravenous infusion. Antimicrob Agents Chemother. 1983 ; 24: 18-22.
9. Wise R., Logan M., Cooper M., Andrews JM Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin. Antimicrob Agents Chemother. 1991 ; 35: 1081-1084.
10. LaFayette AJ Validation of a Method for the Determination of TD-6424, AMI-11352, and AMI-999 in Human Plasma by Liquid Chromatography and Mass Spectroscopy (LC/MS) Detection. Covance Document 7057-192. Madison, WI: Covance ; 2004.
11. Center for Drug Evaluation and Research. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations. Rockville, MD: Food and Drug Administration ; 2003.